Assessing the association between homocysteine and cognition: Reflections on Bradford Hill, meta-analyses, and causality

Nutrition Reviews

Volumn 73, Issue 10, 2015, Pages 723-735

  McCaddon, Andrew ^a   Miller, Joshua W ^b  

^a CARDIFF UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

^b the State University of New Jersey   (United States)

Author keywords

B vitamins; Causality; Cognition; Dementia; Homocysteine

Indexed keywords

APOLIPOPROTEIN E; CHOLESTEROL; CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE; VITAMIN B COMPLEX;

ALZHEIMER DISEASE; ARTICLE; ASSESSMENT OF HUMANS; BRAIN ATROPHY; CHOLESTEROL BLOOD LEVEL; COGNITION; COGNITIVE DEFECT; COGNITIVE FUNCTION TEST; DEMENTIA; DISEASE ASSOCIATION; EDUCATIONAL STATUS; HUMAN; HYPERCHOLESTEROLEMIA; HYPERHOMOCYSTEINEMIA; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; NONHUMAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK REDUCTION; SIR AUSTIN BRADFORD HILL CRITERIA; VITAMIN SUPPLEMENTATION; BLOOD; COGNITION DISORDERS; DIETARY SUPPLEMENT; DRUG EFFECTS; RISK FACTOR;

COGNITION; COGNITION DISORDERS; DEMENTIA; DIETARY SUPPLEMENTS; FOLIC ACID; HOMOCYSTEINE; HUMANS; META-ANALYSIS AS TOPIC; RISK FACTORS; VITAMIN B 12; VITAMIN B 6; VITAMIN B COMPLEX;

EID: 84947743323     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1093/nutrit/nuv022     Document Type: Article

References (70)

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol. 1969;56:111-128.
2. Wilcken DE, Wilcken B. The pathogenesis of coronary artery disease. A possible role for methionine metabolism. J Clin Invest. 1976;57:1079-1082.
3. Refsum H, Ueland PM, Nygard O, et al. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31-62.
4. Rosenberg IH, Miller JW. Nutritional factors in physical and cognitive functions of elderly people. Am J Clin Nutr. 1992;55(suppl 6):1237S-1243S.
5. McCaddon A, Kelly CL. Alzheimer's disease: a 'cobalaminergic' hypothesis. Med Hypotheses. 1992;37:161-165.
6. Regland B, Gottfries CG. Slowed synthesis of DNA and methionine is a pathogenetic mechanism common to dementia in Down's syndrome, AIDS and Alzheimer's disease? Med Hypotheses. 1992;38:11-19.
7. Miller JW. Homocysteine, Alzheimer's disease, and cognitive function. Nutrition. 2000;16:675-677.
8. 12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol. 1998;55:1449-1455.
9. Seshadri S, Beiser A, Selhub J, et al. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med. 2002;346:476-483.
10. Beydoun MA, Beydoun HA, Gamaldo AA, et al. Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic review and meta-analysis. BMC Public Health. 2014;14:643.
11. Clarke R, Bennett D, Parish S, et al. Effects of homocysteine lowering with B vitamins on cognitive aging: meta-analysis of 11 trials with cognitive data on 22, 000 individuals. Am J Clin Nutr. 2014;100:657-666.
12. University of Oxford. Taking B vitamins won't prevent Alzheimer's disease. University of Oxford website: http://www.ox.ac.uk/news/2014-07-15-taking-b-vitamins-won%E2%80%99t-prevent-alzheimer%E2%80%99s-disease. Published July 15, 2014. Accessed September 7, 2014.
13. Hill AB. The environment and disease: association or causation? Proc Royal Soc Med. 1965;58:295-300.
14. Phillips CV, Goodman KJ. The missed lessons of Sir Austin Bradford Hill. Epidemiol Perspect Innov. 2004;1:3.
15. Wald DS, Kasturiratne A, Simmonds M. Serum homocysteine and dementia: metaanalysis of eight cohort studies including 8669 participants. Alzheimers Dement. 2011;7:412-417.
16. Smith AD. The worldwide challenge of the dementias: a role for B vitamins and homocysteine? Food Nutr Bull. 2008;29(suppl 2):S143-S172.
17. Moustafa AA, Hewedi DH, Eissa AM, et al. Homocysteine levels in schizophrenia and affective disorders-focus on cognition. Front Behav Neurosci. 2014;8:343.
18. Obeid R, McCaddon A, Herrmann W. The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases. Clin Chem Lab Med. 2007;45:1590-1606.
19. Miller JW, Selhub J, Nadeau MR, et al. Effect of L-dopa on plasma homocysteine in PD patients: relationship to B-vitamin status. Neurology. 2003;60:1125-1129.
20. McCaddon A, Davies G, Hudson P, et al. Total serum homocysteine in senile dementia of Alzheimer type. Int J Geriatr Psychiatry. 1998;13:235-239.
21. 12 deficiency and Alzheimer disease. Arch Neurol. 2000;57:607-608.
22. Quadri P, Fragiacomo C, Pezzati R, et al. Homocysteine, folate, and vitamin B-12 in mild cognitive impairment, Alzheimer disease, and vascular dementia. Am J Clin Nutr. 2004;80:114-122.
23. Ravaglia G, Forti P, Maioli F, et al. Homocysteine and folate as risk factors for dementia and Alzheimer disease. Am J Clin Nutr. 2005;82:636-643.
24. Haan MN, Miller JW, Aiello AE, et al. Homocysteine, B vitamins, and the incidence of dementia and cognitive impairment: results from the Sacramento Area Latino Study on Aging. Am J Clin Nutr. 2007;85:511-517.
25. Zylberstein DE, Lissner L, Bjorkelund C, et al. Midlife homocysteine and late-life dementia in women. A prospective population study. Neurobiol Aging. 2011;32:380-386.
26. Oulhaj A, Refsum H, Beaumont H, et al. Homocysteine as a predictor of cognitive decline in Alzheimer's disease. Int J Geriatr Psychiatry. 2010;25:82-90.
27. de Jager CA, Oulhaj A, Jacoby R, et al. Cognitive and clinical outcomes of homocysteine-lowering B-vitamin treatment in mild cognitive impairment: a randomized controlled trial. Int J Geriatr Psychiatry. 2012;27:592-600.
28. Tucker KL, Qiao N, Scott T, et al. High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. Am J Clin Nutr. 2005;82:627-635.
29. Hooshmand B, Solomon A, Kareholt I, et al. Associations between serum homocysteine, holotranscobalamin, folate and cognition in the elderly: a longitudinal study. J Intern Med. 2012;271:204-212.
30. McCaddon A. Homocysteine and cognition-"mechanisms." In: B Fowler, ed. Homocysteine Metabolism. Proceedings of the 4th International Conference on Homocysteine Metabolism 2003. Heilbronn, Germany: SPS Publications; 2005:109-122.
31. Kim JM, Lee H, Chang N. Hyperhomocysteinemia due to short-term folate deprivation is related to electron microscopic changes in the rat brain. J Nutr. 2002;132:3418-3421.
32. Jadavji NM, Bahous RH, Deng L, et al. Mouse model for deficiency of methionine synthase reductase exhibits short-term memory impairment and disturbances in brain choline metabolism. Biochem J. 2014;461:205-212.
33. Kruman II, Culmsee C, Chan SL, et al. Homocysteine elicits a DNA damage response in neurons that promotes apoptosis and hypersensitivity to excitotoxicity. J Neurosci. 2000;20:6920-6926.
34. Abushik PA, Niittykoski M, Giniatullina R, et al. The role of NMDA and mGluR5 receptors in calcium mobilization and neurotoxicity of homocysteine in trigeminal and cortical neurons and glial cells. J Neurochem. 2014;129:264-274.
35. Lipton SA, Kim WK, Choi YB, et al. Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA. 1997;94:5923-5928.
36. Hogervorst E, Ribeiro HM, Molyneux A, et al. Plasma homocysteine levels, cerebrovascular risk factors, and cerebral white matter changes (leukoaraiosis) in patients with Alzheimer disease. Arch Neurol. 2002;59:787-793.
37. Ho PI, Collins SC, Dhitavat S, et al. Homocysteine potentiates ß-amyloid neurotoxicity: role of oxidative stress. J Neurochem. 2001;78:249-253.
38. McCaddon A, Hudson PR. Methylation and phosphorylation: a tangled relationship? Clin Chem. 2007;53:999-1000.
39. Obeid R, Kasoha M, Knapp JP, et al. Folate and methylation status in relation to phosphorylated tau Protein (181P) and b-amyloid (1-42) in cerebrospinal fluid. Clin Chem. 2007;53:1129-1136.
40. Sontag E, Nunbhakdi-Craig V, Sontag JM, et al. Protein phosphatase 2A methyltransferase links homocysteine metabolism with tau and amyloid precursor protein regulation. J Neurosci. 2007;27:2751-2759.
41. McCaddon A, Hudson P. Alzheimer's disease, oxidative stress and B-vitamin depletion. Future Neurol. 2007;2:537-547.
42. Hooshmand B, Polvikoski T, Kivipelto M, et al. Plasma homocysteine, Alzheimer and cerebrovascular pathology: a population-based autopsy study. Brain. 2013;136(Pt 9):2707-2716.
43. Smith AD, Smith SM, de Jager CA, et al. Homocysteine-lowering by B vitamins slows the rate of accelerated brain atrophy in mild cognitive impairment: a randomized controlled trial. PLoS One. 2010;5:e12244. doi:10.1371/journal.pone.0012244.
44. Douaud G, Refsum H, de Jager CA, et al. Preventing Alzheimer's disease-related gray matter atrophy by B-vitamin treatment. Proc Natl Acad Sci USA. 2013;110:9523-9528.
45. Stacey M. The fall and rise of Kilmer McCully. NY Times Magazine. 1997;10:25-29.
46. Troen AM, Shukitt-Hale B, Chao WH, et al. The cognitive impact of nutritional homocysteinemia in apolipoprotein-E deficient mice. J Alzheimers Dis. 2006;9:381-392.
47. Minagawa H, Watanabe A, Akatsu H, et al. Homocysteine, another risk factor for Alzheimer disease, impairs apolipoprotein E3 function. J Biol Chem. 2010;285:38382-38388.
48. Eussen SJ, de Groot LC, Joosten LW, et al. Effect of oral vitamin B-12 with or without folic acid on cognitive function in older people with mild vitamin B-12 deficiency: a randomized, placebo-controlled trial. Am J Clin Nutr. 2006;84:361-370.
49. Lewerin C, Matousek M, Steen G, et al. Significant correlations of plasma homocysteine and serum methylmalonic acid with movement and cognitive performance in elderly subjects but no improvement from short-term vitamin therapy: a placebo-controlled randomized study. Am J Clin Nutr. 2005;81:1155-1162.
50. McMahon JA, Green TJ, Skeaff CM, et al. A controlled trial of homocysteine lowering and cognitive performance. N Engl J Med. 2006;354:2764-2772.
51. Durga J, van Boxtel MP, Schouten EG, et al. Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. Lancet. 2007;369:208-216.
52. Stott DJ, MacIntosh G, Lowe GD, et al. Randomized controlled trial of homocysteine-lowering vitamin treatment in elderly patients with vascular disease. Am J Clin Nutr. 2005;82:1320-1326.
53. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006;354:1567-1577.
54. Andreeva VA, Kesse-Guyot E, Barberger-Gateau P, et al. Cognitive function after supplementation with B vitamins and long-chain omega-3 fatty acids: ancillary findings from the SU.FOL.OM3 randomized trial. Am J Clin Nutr. 2011;94:278-286.
55. Kang JH, Cook N, Manson J, et al. A trial of B vitamins and cognitive function among women at high risk of cardiovascular disease. Am J Clin Nutr. 2008;88:1602-1610.
56. Toole JF, Malinow MR, Chambless LE, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004;291:565-575.
57. VITATOPS Trial Study Group. B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol. 2010;9:855-865.
58. 12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial. JAMA. 2010;303:2486-2494.
59. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
60. Brandt J, Spencer M, Folstein MF. The telephone interview for cognitive status. Neuropsych Neuropsychol Behav Neurol. 1988;1:111-117.
61. Welsh KA, Breitner JC, Magruder-Habib KM. Detection of dementia in the elderly using telephone screening of cognitive status. Neuropsych Neuropsychol Behav Neurol. 1993;6:103-110.
62. Deary IJ, Corley J, Gow AJ, et al. Age-associated cognitive decline. Br Med Bull. 2009;92:135-152.
63. Attems J, Jellinger KA. The overlap between vascular disease and Alzheimer's disease-lessons from pathology. BMC Med. 2014;12:206. doi:10.1186/s12916-014-0206-2.
64. Kandel ER, Schwartz JH, Jessell TM. Principles of Neuroscience. 3rd ed. Norwalk, CO; 1991.
65. Aisen PS, Schneider LS, Sano M, et al. High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: a randomized controlled trial. JAMA. 2008;300:1774-1783.
66. Glass GV. Primary, secondary and meta-analysis of research. Educ Res. 1976;5:3-8.
67. Garrard P, Jacoby R. B-vitamin trials meta-analysis: less than meets the eye. Am J Clin Nutr. 2015;101:414-415.
68. Smith AD, de Jager CA, Refsum H, et al. Homocysteine lowering, B vitamins, and cognitive aging. Am J Clin Nutr. 2015;101:415-416.
69. Clarke R, Bennett D, Parish S, et al. Reply to Garrard and Jacoby and Smith et al. Am J Clin Nutr. 2015;101:416-417.
70. 12 deficiency and Alzheimer disease. Neurology. 2002;58:1395-1399.